Goldman Sachs suspended the firm’s rating on Gritstone bio citing insufficient information on which to base an investment view aa result of the “going concern” warning. The analyst anticipates access to capital from either a loan agreement or dilutive financing will be necessary to support the company’s ongoing clinical program for GRANITE.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRTS:
- Gritstone downgraded to Hold from Buy at JonesResearch
- Gritstone downgraded at B. Riley on near-term balance sheet uncertainty
- Gritstone downgraded to Neutral from Buy at B. Riley
- Gritstone downgraded to Neutral from Buy at H.C. Wainwright
- Gritstone downgraded to Market Perform from Outperform at JMP Securities